Walter Maksymowych comments on the ABILITY-3 trial results showing that continued adalimumab treatment is important for the maintenance of remission among patients with nonradiographic axial spondyloarthritis.
08-11-2017 | Axial spondyloarthritis | ACR/ARHP 2017 | Video